Skip to content
OpenCapital
Get started

Catalyst Pharmaceutical CPRX Agamree — Revenue

Other product segments

Product Revenue Net
$149.34M+5.6%
Firdapse
$98.86M+18.1%
Fycompa
$13.77M-61.3%

Similar metrics at other companies

Lantheus Holdings logo
LNTHProduct — Revenue
$369.85M+0.8%
LQD
LQDAProduct — Revenue
$129.88M—
Kiniksa Pharmaceuticals International, plc logo
KNSAProduct — Revenue
$214.27M+55.5%
PTC Therapeutics logo
PTCTProduct — Revenue
$225.57M+47.0%
Axsome Therapeutics logo
AXSMProduct — Revenue
$189.4M+57.4%
BrightSpring Health Services, Inc. logo
BTSGProduct — Revenue
$3.17B+25.2%

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K—
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
Enterprise value$3.09B-4.1%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0×0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's agamree — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's agamree — revenue?
Catalyst Pharmaceutical (CPRX) reported agamree — revenue of $36.71M in Q1 2026.
How has Catalyst Pharmaceutical's agamree — revenue changed year-over-year?
Catalyst Pharmaceutical's agamree — revenue increased by 66.6% year-over-year, from $22.04M to $36.71M.
What does agamree — revenue mean?
This metric represents the total gross revenue generated from the sale of the Agamree product line, excluding any taxes collected from customers. It serves as a primary indicator of the market adoption and commercial performance of this specific therapeutic asset within the company's rare disease portfolio. Tracking this revenue stream allows investors to evaluate the growth trajectory and commercial success of the product following its regulatory approval and market launch.